The share offer capped at $230M has expired. Arbutus (ABUS) announces final results.
Arbutus Biopharma Corporation (ABUS) has announced the final results of its modified Dutch auction tender offer. The offer, which aimed to repurchase common shares for an aggregate price not exceeding US$230 million at prices ranging from US$5.00 to US$5.75 per share, expired on September 29, 2026. This announcement confirms the completion of the share repurchase program.
An up-to-$230M share offer expired; Arbutus Biopharma (ABUS) announced preliminary results.
Arbutus Biopharma (ABUS) announced the preliminary results of its issuer tender offer, which expired on September 29, 2026, at 5:00 p.m. New York City time. The company had offered to repurchase common shares for an aggregate purchase price not exceeding US$230 million, at a price range of US$5.00 to US$5.75 per share in cash. This announcement was made via a press release on September 30, 2026, and an amendment to its Schedule TO filing.
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com
This article is a Form 4 filing for Arbutus Biopharma Corp, dated September 23, 2026. Form 4 is a U.S. Securities and Exchange Commission (SEC) form that must be filed by company insiders to report transactions in their company's stock. The article itself does not contain details of the transactions but serves as a notification of the filing.
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com
This article from Investing.com reports on a Form 4 filing for Arbutus Biopharma Corp (ABUS) related to September 23. Form 4 filings are legally required documents by the SEC for insiders of a company to report changes in their ownership of the company's stock. The article provides minimal detail beyond the announcement of the filing itself.
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com
This article from Investing.com announces the filing of a Form 4 for Arbutus Biopharma Corp on September 23. The Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) when there is a change in the beneficial ownership of a company's stock by insiders. The article provides the ticker symbol ABUS and notes that it experienced a -0.61% change.
Arbutus Biopharma Corp (ABUS) Peer Comparison – Compare with Others
This article provides a peer comparison for Arbutus Biopharma Corp (ABUS) against several other pharmaceutical companies, including Bausch Health Companies (BHC), Cronos Group Inc. (CRON), Sundial Growers - ADR, and Canopy Growth Corp (CGC). It presents detailed financial metrics across market capitalization, revenue, net profit, various ratios (P/E, P/B, cashflow, profitability, growth, valuation, solvency, and operating efficiency), allowing for a direct comparison of their financial health and performance. The data helps investors evaluate ABUS relative to its competitors in the healthcare and pharmaceutical sector.
An 8% holder now reports a passive stake in Arbutus Biopharma (ABUS)
Whitefort Capital and its affiliates have reported a passive 8.0% beneficial stake in Arbutus Biopharma (ABUS) through a Schedule 13G filing. This indicates they no longer seek to influence the company's control, a shift from a previous Schedule 13D filing. The group beneficially owns 15,794,261 common shares, representing 8.0% of the outstanding shares as of September 4, 2026.
ABUS Stock Surges 10% Today — What’s Driving This Super Rally?
Arbutus Biopharma (ABUS) stock surged over 10% in pre-market trading after the company announced its intent to repurchase up to $230 million of its common shares. The company also recently filed international lawsuits to enforce patents protecting its LNP technology against Pfizer and BioNTech. During Q2, Arbutus Biopharma reported revenues of $1.01 million, exceeding estimates, and ended the quarter with $92.6 million in cash, cash equivalents, and marketable securities.
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Arbutus Biopharma Corporation has launched a modified "Dutch Auction" tender offer to repurchase up to US$230 million of its common shares. The offer allows shareholders to tender shares at a price between US$5.00 and US$5.75, aiming to provide liquidity and increase non-tendering shareholders' proportional ownership. This initiative follows the company's receipt of approximately US$178 million from a patent infringement settlement with Moderna.
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares
Arbutus Biopharma has initiated a modified "Dutch Auction" tender offer to repurchase up to $230 million of its common shares, with prices ranging from $5.00 to $5.75 per share. The offer begins on August 24, 2026, and is set to expire on September 29, 2026. This move follows a significant cash inflow from a patent infringement settlement with Moderna, aiming to provide liquidity to shareholders and potentially increase the ownership percentage for non-participating shareholders.
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Arbutus Biopharma Corporation has launched a modified "Dutch Auction" tender offer to repurchase up to US$230 million of its common shares, with a price range of US$5.00 to US$5.75 per share. The offer, which expires on September 29, 2026, allows shareholders to tender shares at a specified auction price, a purchase price to be determined, or proportionately to maintain their ownership. This move follows Arbutus receiving a US$178 million payment from a settlement with Moderna, and the company believes the offer provides an efficient way to return value to shareholders while allowing some to retain their investment.
Arbutus Biopharma stock surges on $230M buyback plan By Investing.com
Arbutus Biopharma (NASDAQ:ABUS) shares surged over 10% in premarket trading after announcing a plan to repurchase up to $230 million of its common shares through a modified Dutch auction tender offer. The buyback is funded by the company's cash on hand, following a settlement with Moderna in March 2026 and an initial payment received in July 2026. The company intends to continue enforcing its lipid nanoparticle technology rights against other infringers like Pfizer and BioNTech.
Arbutus Biopharma (ABUS) 10K Form and Latest SEC Filings 2026
This article provides an overview of Arbutus Biopharma's (ABUS) SEC filings, highlighting that the company has submitted over 366 documents since 2017. It details recent filings including an 8-K current report and a 10-Q quarterly report, and explains the importance of various SEC filing types like 10-K, 10-Q, and 8-K for investors. The article emphasizes that these filings are primary sources of verified financial data for evaluating a company's financial position.
Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma stock surged Friday following the announcement of a planned $230 million share repurchase program through a modified Dutch auction tender offer. The company aims to offer shareholders between $5 and $5.75 per share, funding the buyback with cash on hand, partly derived from a recent settlement with Moderna. Arbutus also continues patent litigation against Pfizer and BioNTech and is developing treatments for chronic hepatitis B.
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback
Arbutus Biopharma Corp (ABUS) has announced its intention to launch a modified "Dutch auction" tender offer to repurchase up to US$230 million of its common shares. The proposed price range for shareholders to tender their shares is US$5.00 to US$5.75 per share. The company noted that the offer has not yet commenced and its terms may change.
Why is Arbutus Biopharma stock surging today?
Arbutus Biopharma (ABUS) stock surged nearly 9.8% after the company announced a modified Dutch auction tender offer to repurchase up to $230 million of its common shares. This buyback is financed by a $950 million payment received from Moderna in July 2026, stemming from a patent infringement settlement. The announcement, coupled with the strengthened cash position, drove the stock to a fresh 52-week high.
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
Arbutus Biopharma (ABUS) shares jumped 10.3% in premarket trading after announcing a $230 million share buyback plan through a modified Dutch auction tender offer. The buyback, financed by existing cash, follows a settlement with Moderna and aims to return capital to shareholders. The offer is expected to launch in August 2026, pending regulatory approvals.
Arbutus Biopharma stock surges on $230M buyback plan
Arbutus Biopharma's stock surged over 10% in premarket trading after the company announced a plan to repurchase up to $230 million of its common shares through a modified Dutch auction tender offer. The buyback, funded by cash on hand, follows a settlement with Moderna and aims to allow shareholders to sell shares within a price range of $5.00 to $5.75. The company intends to continue enforcing its lipid nanoparticle technology rights against other infringers.
Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen
Wall Street Zen downgraded Arbutus Biopharma (NASDAQ:ABUS) from a "buy" to a "hold" rating, though Weiss Ratings simultaneously upgraded it from "sell" to "hold." The biopharmaceutical company holds a consensus "Moderate Buy" rating and a $5.00 price target. Despite missing quarterly EPS estimates by $0.01 with a loss of $0.03 per share, Arbutus Biopharma exceeded revenue expectations at $1.01 million.
Form 8K Arbutus Biopharma Corp For: 12 August By Investing.com
This article reports on an 8K filing by Arbutus Biopharma Corp (ABUS) for August 12. The brief announcement from Investing.com indicates this is a financial market update. No specific details about the content of the 8K filing are provided within the article.
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open
Arbutus Biopharma (ABUS) recently became profitable, with a significant surge in revenue and net income in Q2 2026, leading to a low trailing P/E of 5.6x. Despite this financial improvement, the stock has seen a muted market reaction and recent declines, suggesting investors are uncertain about the sustainability of its profitability and remain focused on its early-stage pipeline. The article highlights both the bullish case for profitability and the bearish concerns regarding clinical risk and share price weakness.
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing
Morgan Stanley and Morgan Stanley Investment Management Inc. have disclosed significant beneficial ownership in Arbutus Biopharma Corp (ABUS) common shares through a Schedule 13G/A filing. As of June 30, 2026, Morgan Stanley reporting units beneficially own 8.8% of Arbutus Biopharma's common shares, while Morgan Stanley Investment Management Inc. holds an 8.7% stake, with both entities exercising shared voting and dispositive power. The filing specifies that it covers only certain Morgan Stanley units and may not include all holdings across the firm.
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
Arbutus Biopharma (NASDAQ:ABUS) reported a quarterly loss of $0.03 per share, missing analyst expectations by $0.01. Despite the earnings miss, the company's revenue of $1.01 million surpassed the consensus estimate of $0.70 million. Following the announcement, ABUS shares declined by 3.0% to $4.53, while institutional ownership of the company increased, with hedge funds and asset managers boosting their positions.
Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact
Arbutus Biopharma Corporation reported its Q2 2026 financial results, showcasing a significant net income of $164,552 thousand for the six months ending June 30, 2026, primarily due to $179,373 thousand in license revenue from Genevant. This marks a substantial improvement from a net loss in the prior year, with total assets and stockholders' equity also seeing considerable increases. Despite a Q2 2026 net loss of $5,143 thousand, the company's overall financial health was bolstered by the Genevant revenue and reduced operating expenses.
Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary
Arbutus Biopharma Corp reported its Q2 2026 results with revenue of $1.01M and a net loss of ($5.14M), a significant decrease from the prior year's $10.74M revenue and $2.52M net income. The diluted EPS was ($0.03) compared to $0.01 a year earlier. Key business highlights include a $178.4M settlement with Moderna, FDA Fast Track designation for Imdusiran, ongoing cost reductions, and continued enforcement of LNP/IP rights.
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average - Should You Sell?
Arbutus Biopharma (NASDAQ:ABUS) shares have moved above their 200-day moving average, reaching $4.67 before closing at $4.59. The company's financial performance includes a quarterly EPS of $0.87 and $179.13 million in revenue, while institutional investors collectively hold 43.79% of its shares. Analyst sentiment is divided, with one Buy and one Sell rating, leading to a consensus Hold rating and a $5.00 price target.
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Arbutus Biopharma Corp (ABUS), highlighting its current earnings forecast score of 9.00 and an average price target of $5.00 from 2 analysts, who recommend a "Strong Buy". It also details expected revenue for the next quarter and past EPS performance.
Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Arbutus Biopharma Corp (ABUS), detailing its current risk score of 5.75 and ranking within the Biotechnology & Medical Research industry. It highlights the company's beta value of 0.63, indicating lower volatility compared to the S&P 500 index. The assessment further breaks down various risk metrics including VaR, maximum drawdown, volatility, and Sharpe Ratios over different periods, offering insights into the stock's performance and risk profile.
Arbutus Biopharma Corp (ABUS) Institutional Confidence
The institutional confidence score for Arbutus Biopharma Corp (ABUS) is 5.00, placing it 132nd within the Biotechnology & Medical Research industry. Institutional shareholding increased by 3.63% quarter-over-quarter, reaching 65.56%. Roivant Sciences Ltd. is the largest institutional shareholder with 38.85M shares, while Morgan Stanley Investment Management Inc. (US) significantly increased its holdings by 9.87%.
Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Arbutus Biopharma Corp (ABUS), noting its current valuation score of 8.62, which ranks it 106 out of 384 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 5.17, significantly above its recent low but below its high. Other key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
ABUS|Arbutus Biopharma Corp|Price:4.280|Chg%:-0.130
TradingKey provides a comprehensive stock analysis of Arbutus Biopharma Corp (ABUS), highlighting its strong fundamentals and high growth potential despite a weak stock market performance. The company's valuation is considered fair, ranking 35th in its industry, with high institutional ownership. Analysts have given it a "Buy" rating with a target price of $5.25.
Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis
Arbutus Biopharma Corp (ABUS) has a strong financial health score of 8.63, ranking 37 out of 386 in the Biotechnology & Medical Research industry, indicating robust financial status and high operating efficiency. The company reported a significant year-over-year revenue increase of 10054.54% to 179.13M, and a net profit increase of 791.90%. Several key financial metrics like cash and cash equivalents, total assets, and free cash flow were not disclosed, and segments like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns also lacked explicit data.
ADAR1 Capital Management LLC Has $14.10 Million Position in Arbutus Biopharma Corporation $ABUS
ADAR1 Capital Management LLC significantly reduced its stake in Arbutus Biopharma Corporation by 42.1% in the first quarter, yet still holds 3.13 million shares valued at $14.10 million. Despite ADAR1's reduction, other institutional investors, such as Goldman Sachs, increased their positions, with institutional investors and hedge funds collectively owning 43.79% of the stock. Analyst sentiment for Arbutus Biopharma is mixed, resulting in a consensus "Hold" rating and a target price of $5.00, while the company reported $0.87 quarterly EPS and $179.13 million in revenue.
Arbutus Biopharma Corp (ABUS) Balance Sheet
This article provides the quarterly and annual balance sheets for Arbutus Biopharma Corp (ABUS), allowing users to evaluate its financial health, analyze fundamentals, and calculate key financial ratios. It includes detailed data on assets, liabilities, and shareholders' equity, covering a historical period. The content also features an FAQ section addressing important balance sheet metrics and specific figures for ABUS's cash, assets, liabilities, and shareholders' equity for the most recent quarter.
Arbutus Biopharma Corp (ABUS) Cash Flow
The article provides a detailed quarterly and annual cash flow statement for Arbutus Biopharma Corp (ABUS), enabling evaluation of its financial soundness. It highlights current operating cash flow at -39.64M in fiscal 2025, which increased by 38.88% year-over-year, and details changes in investing and financing cash flows, including a -5.72M use in financing activities in the latest quarter.
ABUS|Arbutus Biopharma Corp|Price:4.380|Chg%:-0.090
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focusing on infectious diseases, specifically chronic hepatitis B (cHBV). Their pipeline includes imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The article also provides corporate information, executive details, and institutional shareholding data for ABUS.
Arbutus Biopharma Corp (ABUS) Income Statement
This article provides the quarterly and annual income statements for Arbutus Biopharma Corp (ABUS), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It also includes an FAQ section explaining how to read the income statement, distinguishing between quarterly and annual data, defining "YOY," and highlighting key metrics for analyzing ABUS stock performance.
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Arbutus Biopharma Corp (ABUS), focusing on its support and resistance levels, key indicators, and moving averages. As of July 24, 2026, the stock's price momentum score is 4.10, and it is trading between a resistance level of 5.09 and a support level of 3.96. While various technical indicators show a "Neutral" overall signal, moving averages indicate a mix of buy and sell signals.
ABUS|Arbutus Biopharma Corp|Price:4.385|Chg%:-0.085
This article provides a detailed financial overview of Arbutus Biopharma Corp (ABUS), including its latest earnings report, key financial indicators like EPS, revenue, net profit, and margins across quarterly and annual periods. It presents comprehensive income statement, balance sheet, and cash flow statement data, along with answers to frequently asked questions about the company's financials for FY2025.
Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Arbutus Biopharma Corp (ABUS), listing its major shareholders and their proportions, including Roivant Sciences Ltd. and Morgan Stanley Investment Management Inc. It also categorizes shareholders by type and provides a historical overview of institutional holdings, showing changes in the number of institutions and shares held over several quarters. Additionally, it lists ETFs with holdings in ABUS.
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Arbutus Biopharma Corp (ABUS) has an earnings forecast score of 8.67, ranking 72nd in the Biotechnology & Medical Research industry, with an average price target of $5.00 from three analysts. Analysts generally recommend a "Buy" for ABUS stock. The company's expected revenue for the next quarter is $450.00K, and the expected EPS for the next quarter is -$0.03.
ABUS|Arbutus Biopharma Corp|Price:4.460|Chg%:+0.130
Arbutus Biopharma Corp (ABUS) shows healthy fundamentals and high growth potential, with its valuation considered fair within the Biotechnology & Medical Research industry. Institutional ownership is notably high, and analysts currently rate the stock as a "Buy" with a target price reflecting a decent upside. The company is developing therapies for chronic hepatitis B and its stock price is currently in a sideways trend.
Arbutus Plans $230M Buyback as Patent Fight Expands
Arbutus Biopharma Corp. plans to return up to $230 million to shareholders, partially funded by a $178 million settlement from Moderna related to lipid nanoparticle patent infringement. This shareholder return is expected to begin in Q3 2026, pending board approval and receipt of a dividend from Genevant Sciences. Additionally, Arbutus and Genevant have expanded their patent litigation against Pfizer and BioNTech, filing new lawsuits in Canada and Europe over alleged infringement of mRNA vaccine technology.
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT Over Patent Dispute
Arbutus Biopharma (ABUS) and Genevant Sciences have filed three international lawsuits against Pfizer and BioNTech, alleging patent infringement related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a similar U.S. dispute and a $178 million settlement with Moderna. Arbutus Biopharma, a clinical-stage biopharmaceutical company with a perfect financial strength rating (10/10) but low profitability and growth scores, currently has a P/E ratio of 5.5, suggesting it may be undervalued.
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNTech Over Patent Dispute
Arbutus Biopharma (ABUS) and Genevant Sciences have initiated three international lawsuits against Pfizer and BioNTech, alleging patent infringements related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a prior U.S. dispute and a $178 million settlement with Moderna. Despite strong financial stability (10/10), Arbutus has low profitability and growth scores, and its P/E ratio of 5.5 suggests it may be undervalued.
Arbutus (ABUS) Secures $178 Million Settlement with Moderna
Arbutus Biopharma Corp (ABUS) has secured a $178 million settlement with Moderna to resolve patent infringement disputes related to Moderna’s COVID-19 vaccines. This payment will bolster Arbutus's cash reserves and allow it to focus on its core business of developing therapeutics for infectious diseases. Despite strong financial strength, Arbutus's low profitability and growth ranks, coupled with a "Possible Value Trap" classification, suggest investors should proceed with caution.
ARBUTUS BIOPHARMA CORP - EXPECTS TO RETURN UP TO $230 MLN IN CAPITAL TO SHAREHOLDERS
ARBUTUS BIOPHARMA CORP announced its intention to return up to $230 million in capital to its shareholders. This significant capital return initiative reflects the company's financial strength and commitment to delivering shareholder value.
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return
Arbutus Biopharma and its licensee Genevant have filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their lipid nanoparticle technology, seeking monetary damages and injunctions. This follows Arbutus receiving approximately $178 million from Moderna to settle a similar patent dispute. Arbutus also expects a dividend from Genevant in Q3 2026 and plans to return up to $230 million in capital to shareholders through share repurchases, contingent on board approval and the dividend receipt.
Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback
Arbutus Biopharma received approximately $178 million from a settlement with Moderna regarding mRNA patent disputes and may receive up to an additional $1.3 billion. The company also announced plans to return up to $230 million to shareholders through common share repurchases, contingent on board approval and a dividend from Genevant. Additionally, Arbutus and Genevant have initiated three international patent infringement lawsuits against Pfizer/BioNTech over lipid nanoparticle technology.
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus Biopharma, and its licensee Genevant, have initiated three international lawsuits against Pfizer and BioNTech for patent infringement related to their innovative LNP technology used in COVID-19 vaccines. Concurrently, Arbutus announced the receipt of approximately $178 million from Moderna as part of a previous settlement agreement and plans to return up to $230 million in capital to shareholders, commencing in Q3 2026. The company also anticipates receiving a dividend from Genevant's parent in Q3 2026.
